ANRO
Alto Neuroscience, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Neutral
+2/100
Last price
23.50
▼ 0.51 (2.12%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
24.20
Prev close
24.01
Day high
24.70
Day low
23.50
Volume
576.25K
Market cap
$929.65M
P/E (TTM)
—
52W range
5.23 – 37.48
Day trading desk
Gap from prior close
+0.79%
Prior close 24.01
VWAP
23.79
-1.23% from price
Relative volume
2.48×
Unusually busy
Session range
12.77%
23.50 – 26.50
Position in range
0%
Near session low
ATR (14D)
1.77
7.55% of price
Prior day high
25.85
PDH
Prior day low
23.80
PDL
Bid / ask spread
—
Quote not published
Session volume
1.36M
Avg 548.03K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.87%
-12.8%
1M
-33.36%
-34.5%
3M
-9.20%
-13.7%
6M
+10.96%
-7.2%
YTD
+33.09%
+18.8%
1Y
+243.83%
+227.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on ANRO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.60M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 14, 26 | ETKIN AMIT Chief Executive Officer |
STOCK | 400.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ETKIN AMIT |
Chief Executive Officer | 833.95K | Stock Gift |
Fundamentals
Market cap$929.65M
Enterprise value$709.21M
Revenue (TTM)—
Gross profit—
EBITDA$-87.58M
Net income$-84.24M
EPS (TTM)$-2.31
Free cash flow$-42.90M
Total cash$243.73M
Total debt$23.29M
Book value / share$6.25
Shares outstanding39.24M
Float29.65M
Short % of float12.46%
Dividend yield0.00%
Beta (5Y)1.34
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.21
PEG ratio—
Price / sales—
Price / book3.79
EV / revenue—
EV / EBITDA-8.10
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-49.17%
Return on assets-26.79%
Debt / equity10.62
Current ratio14.85
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $45.62M | $47.00M | $30.29M | $23.69M | -2.9% |
| Selling, general & admin | $20.75M | $21.61M | $7.52M | $5.50M | -4.0% |
| Total operating expense | $66.36M | $68.61M | $37.81M | $27.45M | -3.3% |
| Operating income | -$66.36M | -$68.61M | -$37.81M | -$27.45M | +3.3% |
| Net interest income | $4.13M | $7.48M | $979.00K | $114.00K | -44.7% |
| Pre-tax income | -$63.24M | -$61.43M | -$36.30M | -$27.71M | -2.9% |
| Net income | -$63.24M | -$61.43M | -$36.30M | -$27.71M | -2.9% |
| Net income to common | -$63.24M | -$61.43M | -$36.30M | -$27.71M | -2.9% |
| Basic EPS | -2.19 | -2.50 | -1.42 | -2.13 | +12.4% |
| Diluted EPS | -2.19 | -2.50 | -1.42 | -2.13 | +12.4% |
| EBIT | -$60.77M | -$60.06M | -$34.94M | -$27.71M | -1.2% |
| EBITDA | -$60.11M | -$59.55M | -$34.56M | -$27.37M | -0.9% |
| Basic shares | 28.85M | 24.60M | 25.57M | 12.98M | +17.3% |
| Diluted shares | 28.85M | 24.60M | 25.57M | 12.98M | +17.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $176.48M | $168.23M | $82.55M | $48.34M | — | +4.9% |
| Cash & short-term investments | $176.48M | $168.23M | $82.55M | $48.34M | — | +4.9% |
| Accounts receivable | — | — | — | $333.00K | $1.50M | — |
| Total current assets | $177.72M | $169.34M | $85.39M | $49.22M | — | +4.9% |
| Property, plant & equipment | $6.13M | $7.70M | $1.11M | $1.17M | — | -20.4% |
| Total assets | $184.69M | $177.54M | $86.63M | $50.85M | — | +4.0% |
| Total current liabilities | $11.32M | $10.01M | $5.61M | $5.56M | — | +13.2% |
| Current debt | $585.00K | — | — | — | — | — |
| Long-term debt | $18.40M | $11.56M | $9.86M | $9.46M | — | +59.2% |
| Total debt | $23.96M | $16.94M | $9.99M | $9.75M | — | +41.4% |
| Total liabilities | $33.55M | $26.08M | $158.30M | $89.26M | — | +28.6% |
| Retained earnings | -$201.63M | -$138.40M | -$76.97M | -$40.66M | — | -45.7% |
| Shareholder equity | $151.14M | $151.46M | -$71.67M | -$38.41M | — | -0.2% |
| Working capital | $166.39M | $159.33M | $79.78M | $43.66M | — | +4.4% |
| Net tangible assets | $151.14M | $151.46M | -$71.67M | -$38.41M | — | -0.2% |
| Shares issued | 31.92M | 26.99M | 25.57M | 25.57M | — | +18.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$63.24M | -$61.43M | -$36.30M | -$27.71M | -2.9% |
| Depreciation & amortisation | $661.00K | $502.00K | $373.00K | $342.00K | +31.7% |
| Stock-based compensation | $8.11M | $7.63M | $2.89M | $1.76M | +6.3% |
| Change in working capital | $33.00K | $4.06M | -$698.00K | $4.58M | -99.2% |
| Operating cash flow | -$51.77M | -$47.42M | -$33.45M | -$20.39M | -9.2% |
| Capital expenditure | -$24.00K | -$2.08M | -$470.00K | -$732.00K | +98.8% |
| Investing cash flow | -$24.00K | -$2.08M | -$470.00K | -$732.00K | +98.8% |
| Share buybacks | -$167.00K | $0 | — | — | — |
| Financing cash flow | $60.08M | $135.69M | $68.13M | $43.79M | -55.7% |
| Free cash flow | -$51.79M | -$49.50M | -$33.92M | -$21.13M | -4.6% |
| End cash position | $176.98M | $168.73M | $82.55M | $48.34M | +4.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $22.11M | $20.29M | $12.00M | $10.53M | $13.12M | — | +8.9% |
| Selling, general & admin | $7.02M | $6.84M | $5.06M | $4.43M | $5.56M | — | +2.6% |
| Total operating expense | $29.13M | $27.14M | $17.05M | $14.95M | $18.68M | — | +7.3% |
| Operating income | -$29.13M | -$27.14M | -$17.05M | -$14.95M | -$18.68M | — | -7.3% |
| Net interest income | $1.62M | $1.02M | $986.00K | $882.00K | $1.04M | — | +59.5% |
| Pre-tax income | -$27.64M | -$26.24M | -$16.18M | -$14.18M | -$17.71M | — | -5.3% |
| Net income | -$27.64M | -$26.24M | -$16.18M | -$14.18M | -$17.71M | — | -5.3% |
| Net income to common | -$27.64M | -$26.24M | -$16.18M | -$14.18M | -$17.71M | — | -5.3% |
| Basic EPS | -0.65 | -0.80 | — | -0.52 | -0.65 | -0.56 | +18.8% |
| Diluted EPS | -0.65 | -0.80 | — | -0.52 | -0.65 | -0.56 | +18.8% |
| EBIT | -$27.15M | -$25.69M | -$15.61M | -$13.53M | -$17.06M | — | -5.7% |
| EBITDA | -$26.96M | -$25.51M | -$15.45M | -$13.37M | -$16.89M | — | -5.7% |
| Basic shares | 42.81M | 32.89M | — | 27.10M | 27.07M | 27.05M | +30.2% |
| Diluted shares | 42.81M | 32.89M | — | 27.10M | 27.07M | 27.05M | +30.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $243.73M | $263.76M | $176.48M | $137.82M | $147.59M | -7.6% |
| Cash & short-term investments | $243.73M | $263.76M | $176.48M | $137.82M | $147.59M | -7.6% |
| Total current assets | $247.32M | $269.13M | $177.72M | $139.45M | $149.85M | -8.1% |
| Property, plant & equipment | $5.91M | $6.29M | $6.13M | $6.49M | $6.96M | -6.1% |
| Total assets | $254.07M | $276.26M | $184.69M | $147.01M | $157.88M | -8.0% |
| Total current liabilities | $16.65M | $13.12M | $11.32M | $9.04M | $8.13M | +27.0% |
| Current debt | $3.77M | $2.14M | $585.00K | — | — | +76.4% |
| Long-term debt | $14.88M | $16.22M | $18.40M | $22.44M | $22.12M | -8.2% |
| Total debt | $23.29M | $23.21M | $23.96M | $27.52M | $27.31M | +0.3% |
| Total liabilities | $34.82M | $32.89M | $33.55M | $35.45M | $34.47M | +5.9% |
| Retained earnings | -$255.51M | -$227.87M | -$201.63M | -$185.45M | -$171.27M | -12.1% |
| Shareholder equity | $219.25M | $243.37M | $151.14M | $111.56M | $123.41M | -9.9% |
| Working capital | $230.67M | $256.01M | $166.39M | $130.40M | $141.72M | -9.9% |
| Net tangible assets | $219.25M | $243.37M | $151.14M | $111.56M | $123.41M | -9.9% |
| Shares issued | 35.09M | 35.05M | 31.92M | 27.17M | 27.07M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$27.64M | -$26.24M | -$16.18M | -$14.18M | -$17.71M | — | -5.3% |
| Depreciation & amortisation | $184.00K | $184.00K | $157.00K | $164.00K | $169.00K | — | 0.0% |
| Stock-based compensation | $3.55M | $2.82M | $1.95M | $2.19M | $2.00M | — | +25.8% |
| Change in working capital | $3.64M | -$4.39M | $2.10M | $1.30M | $1.29M | — | +182.9% |
| Operating cash flow | -$19.76M | -$27.09M | -$11.52M | -$9.92M | -$13.78M | — | +27.1% |
| Capital expenditure | — | -$556.00K | — | — | — | -$24.00K | — |
| Investing cash flow | $0 | -$556.00K | $0 | $0 | $0 | — | +100.0% |
| Share buybacks | -$538.00K | -$4.88M | — | — | $0 | $0 | +89.0% |
| Financing cash flow | -$273.00K | $114.94M | $50.19M | $153.00K | $613.00K | — | -100.2% |
| Free cash flow | -$19.76M | -$27.65M | -$11.52M | -$9.92M | -$13.78M | — | +28.5% |
| End cash position | $244.23M | $264.26M | $176.98M | $138.32M | $148.09M | — | -7.6% |
Options analytics
Put / call volume
0.86
Call-heavy session
Put / call open interest
0.44
Positioning, not flow
Max pain
2.50
-89.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
51
Contracts, this expiry
Put volume
44
Contracts, this expiry
Heaviest call OI
2.50
40 contracts
Heaviest put OI
2.50
20 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.77 | -0.65 | +16.0% |
| Mar 2026 | -0.51 | -0.80 | -58.4% |
| Dec 2025 | -0.51 | -0.45 | +11.8% |
| Sep 2025 | -0.64 | -0.52 | +18.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.70 | 7 | $0 | 0.0% |
| Next quarter | -0.73 | 7 | $0 | 0.0% |
| Current year | -2.92 | 6 | $0 | 0.0% |
| Next year | -3.29 | 7 | $0 | 0.0% |
Analyst targets & ownership
Mean target$38.38
High target$55.00
Low target$26.00
Implied upside63.33%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy0 / 10
Hold1
Sell / Strong sell0 / 0
Held by insiders4.07%
Held by institutions87.10%
Institutions holding164
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
25.78
-8.83% from price
SMA 20
28.50
-16.89% from price
SMA 50
30.76
-22.98% from price
SMA 100
27.18
-13.53% from price
SMA 200
23.78
-0.38% from price
EMA 12
26.43
-11.08% from price
EMA 26
28.58
-17.77% from price
EMA 50
29.17
-19.43% from price
RSI (14)
22.4
Oversold
MACD (12,26,9)
-2.15
Hist -0.58
ATR (14)
1.77
7.49% of price
Realised vol 30D
47.0%
Annualised
Bollinger upper
34.47
20, 2σ
Bollinger lower
22.54
20, 2σ
50 / 200 cross
Golden
30.76 vs 23.78
Trend bias
Below 200
-0.38%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.34
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
47.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-35.3%
Peak to trough
Max drawdown 5Y
-91.7%
Peak to trough
ATR 14
1.77
7.49% of price
Beta (reported)
1.34
5Y monthly, from filing
Short interest
Shares short
4.17M
Prior 3.56M
Change vs prior
+17.4%
Shorts adding
% of float
12.46%
Elevated
% of shares out
10.64%
Against total outstanding
Days to cover
8.9
Crowded exit
Float
29.65M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 13, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Aug 13, 26 | BTIG | MAINTAINED | Buy | Buy |
| May 18, 26 | Baird | MAINTAINED | Outperform | Outperform |
| May 14, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| May 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 22, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Apr 2, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Apr 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 2, 26 | Jones Trading | MAINTAINED | Buy | Buy |
| Apr 2, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Apr 2, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-27
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-14
Corporate Changes & Voting Matters
8-K · 2026-07-13
Corporate Changes & Voting Matters
8-K · 2026-05-28
Periodic Financial Reports
10-Q · 2026-05-13
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-04-17
Offering Registrations
S-3 · 2026-04-10
Headlines
Alto Neuroscience Insider Sold Shares Worth $3,567,247, According to a Recent SEC Filing
MT Newswires · 5d ago
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Business Wire · 28d ago
Alto Neuroscience Promotes Nick Smith to President and CFO
MT Newswires · 40d ago
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Business Wire · 40d ago
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
Simply Wall St. · 51d ago
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?
Simply Wall St. · 52d ago
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans
Simply Wall St. · 52d ago
BofA Adjusts Price Target on Alto Neuroscience to $37 From $33
MT Newswires · 54d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.